Form 4: IRADIMED Director Sells 1,000 Shares Under 10b5-1 Plan

IRADIMED Corp. Director Monty K. Allen sold 1,000 shares of common stock for $100.2563 per share on February 13, 2026, under a Rule 10b5-1 plan.

Summary

• Monty K. Allen, a Director of IRADIMED CORP (IRMD), reported a transaction involving the disposition of common stock.
• The transaction occurred on February 13, 2026, and involved the sale of 1,000 shares of IRMD common stock.
• The shares were sold at a weighted average price of $100.2563 per share, with individual trades ranging from $100.00 to $100.26.
• Following this sale, Monty K. Allen directly beneficially owns 21,000 shares of IRMD common stock.
• The transaction was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. A director's sale of shares, while a disposition, was executed under a pre-arranged 10b5-1 plan, which typically reduces the immediate negative signaling often associated with insider sales.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even those executed under a Rule 10b5-1 plan, are routinely monitored by investors for insights into management's perspective on future company performance. While 10b5-1 plans are pre-arranged to avoid accusations of trading on material non-public information, the decision to establish such a plan and the timing of sales can still be a point of interest.

Stakeholder Impact

• Shareholders may note the director's sale, which could be interpreted in various ways depending on the context of the company's stock performance and the director's overall holdings.

Key Dates

Recommendation

The sale by a director, Monty K. Allen, of 1,000 shares of IRADIMED common stock was executed under a pre-arranged Rule 10b5-1 plan. Such plans are established in advance to allow insiders to sell shares without being accused of trading on material non-public information. While any insider sale warrants attention, this specific transaction, given its nature and relatively small size compared to the company's overall market capitalization, does not provide a strong signal for a change in investment thesis. Investors should continue to hold and evaluate IRMD based on its broader financial performance and strategic developments rather than this single insider transaction.

Keywords

IRADIMED, IRMD, Form 4, Insider Trading, Stock Sale, Director, Monty K. Allen, 10b5-1 Plan